Velasibor-B (09887): LBL-034 clinical study selected to make the first oral presentation at the 67th ASH annual meeting.

Zhtng Cijng APP News, Wilzh B-B (09887) issued an announcement, regarding the selection of 5 research abstracts for presentation at the 67th Annual Meeting of the American Society of Hematology. The company gladly provided further details on its research and development of innovative drugs LBL-034 and LBL-076, with multiple research abstracts being included in the 67th ASH Annual Meeting. Among them, one clinical study on LBL-034 was selected to be the first oral presentation on the opening day of the conference, showcasing the latest efficacy and safety data of LBL-034 for relapsed/refractory multiple myeloma patients.